{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:29:19Z","timestamp":1791224959931,"version":"4.1.0"},"reference-count":43,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002647","name":"Sung Kyun Kwan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,5,25]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Targeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which is a master regulator of DDR. We conducted a phase II trial of ceralasertib plus durvalumab in patients with previously treated advanced gastric cancer (AGC) to demonstrate the safety, tolerability, and clinical activity of the combination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase II, open-label, single-center, non-randomized study was designed to evaluate the efficacy and safety of ceralasertib in combination with durvalumab in patients with AGC. The study drug regimen was ceralasertib (240 mg two times a day) days 15\u201328 in a 28-day cycle in combination with durvalumab (1500 mg) at day 1 every 4 weeks. The primary end point was overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (V.1.1). Exploratory biomarker analysis was performed using fresh tumor biopsies in all enrolled patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 31 patients, the ORR, disease control rate, median progression-free survival (PFS), and overall survival were 22.6% (95% CI 9.6% to 41.1%), 58.1% (95% CI 39.1% to 75.5%), 3.0 (95% CI 2.1 to 3.9) months, and 6.7 (95% CI 3.8 to 9.6) months, respectively. Common adverse events were manageable with dose modification. A subgroup of patients with a loss of ataxia telangiectasia mutated (ATM) expression and\/or high proportion of mutational signature attributable to homologous repair deficiency (sig. HRD) demonstrated a significantly longer PFS than those with intact ATM and low sig. HRD (5.60 vs 1.65 months; HR 0.13, 95% CI 0.045 to 0.39; long-rank p&lt;0.001). During the study treatment, upregulation of the innate immune response by cytosolic DNA, activation of intratumoral lymphocytes, and expansion of circulating tumor-reactive CD8 +T cell clones were identified in responders. Enrichment of the tumor vasculature signature was associated with treatment resistance.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ceralasertib plus durvalumab has promising antitumor activity, with durable responses in patients with refractory AGC. Thus, a biomarker-driven trial is required.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03780608\">NCT03780608<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005041","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T12:18:05Z","timestamp":1657023485000},"page":"e005041","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":89,"title":["Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03780608","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Minsuk","family":"Kwon","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"Department of Hematology-Oncology, Ajou University, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gahyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Republic of Korea"},{"name":"Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryul","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Tae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Physiology, Ajou University, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Smith","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G S","family":"Mortimer","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsene-Bienvenu","family":"Loemb\u00e9","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Irurzun-Arana","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loumpiana","family":"Koulai","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-9205","authenticated-orcid":false,"given":"Kyoung-Mee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Dean","sequence":"additional","affiliation":[{"name":"Oncology R&D, AstraZeneca, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woong-Yang","family":"Park","sequence":"additional","affiliation":[{"name":"Samsung Genome Institute, Samsung Medical Center, Gangnam-gu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"},{"name":"Department of Intelligent Precision Healthcare Convergence, Sungkyunkwan University, Suwon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"2025100301342520000_10.7.e005041.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5"},{"key":"2025100301342520000_10.7.e005041.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"2025100301342520000_10.7.e005041.3","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0737"},{"key":"2025100301342520000_10.7.e005041.4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS263","article-title":"Pembrolizumab plus chemotherapy for previously untreated, HER2-negative unresectable or metastatic advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma: KEYNOTE-859","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100301342520000_10.7.e005041.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z"},{"key":"2025100301342520000_10.7.e005041.6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41416-021-01425-7","article-title":"Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers","volume":"125","author":"Baxter","year":"2021","journal-title":"Br J Cancer"},{"key":"2025100301342520000_10.7.e005041.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1709968"},{"key":"2025100301342520000_10.7.e005041.8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/bjc.2017.376","article-title":"Combining DNA damaging therapeutics with immunotherapy: more haste, less speed","volume":"118","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100301342520000_10.7.e005041.9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0226"},{"key":"2025100301342520000_10.7.e005041.10","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0784-8"},{"key":"2025100301342520000_10.7.e005041.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2017.05.015"},{"key":"2025100301342520000_10.7.e005041.12","first-page":"16","article-title":"PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"2025100301342520000_10.7.e005041.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0251"},{"key":"2025100301342520000_10.7.e005041.14","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jtho.2021.01.299","article-title":"OA07.08 HUDSON: an open-label, multi-drug, biomarker-directed, phase II platform study in patients with NSCLC, who progressed on anti-PD(L)1 therapy","volume":"16","author":"Besse","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100301342520000_10.7.e005041.15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann Oncol"},{"key":"2025100301342520000_10.7.e005041.16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1544442","article-title":"PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer","volume":"8","author":"Angell","year":"2019","journal-title":"Oncoimmunology"},{"key":"2025100301342520000_10.7.e005041.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.02.060"},{"key":"2025100301342520000_10.7.e005041.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15912-7","article-title":"Mutational signatures are jointly shaped by DNA damage and repair","volume":"11","author":"Volkova","year":"2020","journal-title":"Nat Commun"},{"key":"2025100301342520000_10.7.e005041.19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41590-020-0762-x","article-title":"Single-cell landscape of immunological responses in patients with COVID-19","volume":"21","author":"Zhang","year":"2020","journal-title":"Nat Immunol"},{"key":"2025100301342520000_10.7.e005041.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3"},{"key":"2025100301342520000_10.7.e005041.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat Commun"},{"key":"2025100301342520000_10.7.e005041.22","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCELL.2021.04.014"},{"key":"2025100301342520000_10.7.e005041.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2443"},{"key":"2025100301342520000_10.7.e005041.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"2025100301342520000_10.7.e005041.25","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100301342520000_10.7.e005041.26","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.21037\/jgo.2018.09.04","article-title":"Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy","volume":"9","author":"Klempner","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"2025100301342520000_10.7.e005041.27","doi-asserted-by":"publisher","DOI":"10.1159\/000346034"},{"key":"2025100301342520000_10.7.e005041.28","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0860"},{"key":"2025100301342520000_10.7.e005041.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"2025100301342520000_10.7.e005041.30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"2025100301342520000_10.7.e005041.31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.TM118.000372"},{"key":"2025100301342520000_10.7.e005041.32","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"2025100301342520000_10.7.e005041.33","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3934"},{"key":"2025100301342520000_10.7.e005041.34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0761"},{"key":"2025100301342520000_10.7.e005041.35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0113169"},{"key":"2025100301342520000_10.7.e005041.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1941"},{"key":"2025100301342520000_10.7.e005041.37","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4292"},{"key":"2025100301342520000_10.7.e005041.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0130-2"},{"key":"2025100301342520000_10.7.e005041.39","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","article-title":"Peripheral T cell expansion predicts tumour infiltration and clinical response","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"2025100301342520000_10.7.e005041.40","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx238"},{"key":"2025100301342520000_10.7.e005041.41","doi-asserted-by":"publisher","DOI":"10.1038\/nature13480"},{"key":"2025100301342520000_10.7.e005041.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.039"},{"key":"2025100301342520000_10.7.e005041.43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01803","article-title":"Prediction of specific TCR-peptide binding from large dictionaries of TCR-peptide pairs","volume":"11","author":"Springer","year":"2020","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:34:33Z","timestamp":1759480473000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,5]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/jitc-2022-005041"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005041","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}